MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 126949 | Name: Batanopride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Batanopride, previously known as BMY-25801, a 5-hydroxytryptamine 3 receptor antagonist, was studied against emesis for cancer patients that were treated by chemotherapy procedure.

Chemical Structure

Batanopride
Batanopride
CAS#102670-46-2 (free base)

Theoretical Analysis

MedKoo Cat#: 126949

Name: Batanopride

CAS#: 102670-46-2 (free base)

Chemical Formula: C17H26ClN3O3

Exact Mass: 355.1663

Molecular Weight: 355.86

Elemental Analysis: C, 57.38; H, 7.36; Cl, 9.96; N, 11.81; O, 13.49

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
102670-46-2 (free base) 122452-31-7 (2HCl) 102670-59-7 (HCl) 112538-76-8 (3HCl)
Synonym
Batanopride; BMY-25801; BMY25801; BMY 25801
IUPAC/Chemical Name
4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-((3-oxobutan-2-yl)oxy)benzamide
InChi Key
ZYOJXUNLLOBURP-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H26ClN3O3/c1-5-21(6-2)8-7-20-17(23)13-9-14(18)15(19)10-16(13)24-12(4)11(3)22/h9-10,12H,5-8,19H2,1-4H3,(H,20,23)
SMILES Code
CCN(CC)CCNC(=O)C1=C(OC(C)C(C)=O)C=C(N)C(Cl)=C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 355.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Pater J, Slamet L, Zee B, Osoba D, Warr D, Rusthoven J. Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. Support Care Cancer. 1994 May;2(3):161-6. doi: 10.1007/BF00417474. PMID: 8032701. 2: St Peter JV, Brady ME, Foote EF, Dandekar KA, Smaldone L, Pykkonen JL, Keane WF, Halstenson CE. The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment. Eur J Clin Pharmacol. 1993;45(1):59-63. doi: 10.1007/BF00315351. PMID: 8405031. 3: Nassar MN, House CA, Agharkar SN. Stability of batanopride hydrochloride in aqueous solutions. J Pharm Sci. 1992 Nov;81(11):1088-91. doi: 10.1002/jps.2600811109. PMID: 1447710. 4: Rusthoven J, Pater J, Kaizer L, Wilson K, Osoba D, Latreille J, Findlay B, Lofters WS, Warr D, Laberge F, et al. A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy. Ann Oncol. 1991 Oct;2(9):681-6. doi: 10.1093/oxfordjournals.annonc.a058049. PMID: 1742224. 5: Aapro MS. 5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs. 1991 Oct;42(4):551-68. doi: 10.2165/00003495-199142040-00002. PMID: 1723361. 6: Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst. 1991 May 1;83(9):613-20. doi: 10.1093/jnci/83.9.613. PMID: 1850806. 7: Herrstedt J, Jeppesen BH, Dombernowsky P. Dose-limiting hypotension with the 5-HT3-antagonist batanopride (BMY-25801). Ann Oncol. 1991 Feb;2(2):154-5. doi: 10.1093/oxfordjournals.annonc.a057882. PMID: 2054319. 8: Fleming GF, Vokes EE, McEvilly JM, Janisch L, Francher D, Smaldone L. Double- blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis. Cancer Chemother Pharmacol. 1991;28(3):226-7. doi: 10.1007/BF00685516. PMID: 1855280. 9: Smaldone L, Plezia P, Alberts D, Aapro M, Sartiano G, Dorn M, Brady M, Comerski C, Schwartz SE, Fairchild C, et al. Batanopride (BMY-25801): a new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis. Cancer Treat Rev. 1990 Sep;17(2-3):319-27. doi: 10.1016/0305-7372(90)90064-m. PMID: 2272047. 10: King GL, Landauer MR. Effects of zacopride and BMY25801 (batanopride) on radiation-induced emesis and locomotor behavior in the ferret. J Pharmacol Exp Ther. 1990 Jun;253(3):1026-33. PMID: 2359014. 11: King GL. Emesis and defecations induced by the 5-hydroxytryptamine (5-HT3) receptor antagonist zacopride in the ferret. J Pharmacol Exp Ther. 1990 Jun;253(3):1034-41. PMID: 2162943. 12: Gylys JA, Wright RN, Nicolosi WD, Buyniski JP, Crenshaw RR. BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties. J Pharmacol Exp Ther. 1988 Mar;244(3):830-7. PMID: 2978041.

View History

Batefenterol

Batefenterol

New Featured